A new microbiome sequencing and analysis company has been launched in the probiotic research capital of the world, County Cork, Ireland. SeqBiome is a spin-out company from APC Microbiome Ireland, SFI Research Centre, UCC and Teagasc (The Irish Agriculture and Food Development Authority) that aims to provide microbiome insights for clients in pharmaceuticals, nutrition, sport, healthcare and food industries.

It is the fifth APC spin-out company, following in the footsteps of Atlantia Food Clinical Trials Ltd, Artugen Therapeutics, 4D Pharma Cork Ltd, and PrecisionBiotics Ltd. They now make up some of the clients for SeqBiome alongside food industry giants; Nestle and MARS Petcare. 

Co-Founders of SeqBiome, Dr Marcus Claesson (CEO), Prof Paul Cotter (CTO) and Brad Wrigley (Executive Director) have over 40 years of combined published microbiome experience, with over 350 papers and 23,000 citations. 

Speaking at the launch, Marcus Claesson, SeqBiome founder and CEO, commented; "For many Pharma, Nutrition, Sport, Agriculture and Healthcare companies, microbiome analysis is a complex and time-consuming process. It requires the support of expensive sequencing facilities, significant computational power and extensive expertise in bioinformatic analysis and interpretation."

"Without these in-house capabilities, commercial organizations struggle to derive meaningful and reliable information about their products and their impact on the microbiome. We're building a vastly experienced team with a shared vision to help these and other organizations develop world-class products that make a real difference to microbiome health", Marcus concluded. 

Dr Fiona Crispie and Dr Orla O Sullivan have also been recognized for their outstanding work at Teagasc in getting SeqBiome of the ground.